Abbott Laboratories (ABT) 2024 10-K Earnings Analysis
Abbott Laboratories2024 Earnings Analysis
80/100
Abbott's FY2024 shows diversification working as designed: $42.0B revenue, $13.4B net income, and $6.4B free cash flow in a year when COVID-testing demand was no longer distorting the comparison set. This is not a single-franchise healthcare story; it is a portfolio of installed-base and repeat-use businesses led by Libre, structural heart, nutrition, and established pharma. The quality question is less about cyclicality than about where the next leg of growth comes from once diagnostics normalization is fully behind the company.
Filing analysis
Abbott Laboratories 2024 10-K Analysis
This page reads Abbott Laboratories's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 80/100, or grade B.
ABT Earnings Quality
The earnings-quality module scores 80/100, with Gross Margin: 55.4%, Operating Margin: 16.3%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
ABT Economic Moat Analysis
The moat-strength module scores 85/100, with FreeStyle Libre: CGM franchise, Structural Heart & CRM: Interventional leadership. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
ABT Free Cash Flow vs Net Income
CF/Net Income: 0.64x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 82/100. For the diagnostic, start with cash flow vs net income.
ABT Key Risks from the Annual Report
The risk module scores 72/100, with Diagnostics Normalization: Post-COVID, Nutrition Litigation: NEC litigation. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is ABT a High Quality Earnings Stock?
Based on this 2024 filing, ABT passes the first screen for high-quality earnings: the overall grade is B, and the earnings-quality score is 80/100. This is a research screen, not investment advice.
Read the report first
Understand Abbott Laboratories first, then decide if it belongs on your watchlist
The ABT score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep ABT with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the ABT report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 55.4% reflects the diversified-healthcare cost structure across branded pharma, medical-devices, diagnostics, and consumer-nutrition products. Segment-level gross-margin variation is disclosed in the segment footnote.
Per the FY2024 10-K income statement, operating margin of 16.3% reflects the post-pandemic diagnostics normalization (COVID-testing revenue tapering) alongside Medical Devices expansion (FreeStyle Libre continuous-glucose monitoring, structural heart, neuromodulation per the segment disclosures).
Per the FY2024 cash flow statement, OCF of $8.6B against NI of $13.4B gives a 0.64x CF/NI ratio. The ratio below 1x reflects non-cash items in NI (including investment-related gains disclosed in the income statement) that exceed the non-cash items in OCF; core-operating cash generation is better read directly from OCF.
Per the FY2024 segment disclosures, Abbott operates Established Pharmaceuticals (international branded generics), Nutrition (Similac infant, Ensure adult, PediaSure), Diagnostics (core lab, rapid, molecular, point-of-care), and Medical Devices (diabetes care — FreeStyle Libre, structural heart, cardiac rhythm management, neuromodulation, vascular).
Earnings quality scores 80/100. Per the FY2024 10-K, Abbott's $42.0B revenue produces a 55.4% gross margin and 16.3% operating margin. The 0.64x CF/NI ratio is below 1x in the current period because reported net income includes non-cash investment-related gains disclosed in the income statement; operating cash generation is better read directly from the $8.6B OCF. The four-segment structure diversifies across branded pharma, nutrition, diagnostics, and medical devices.
Moat Strength
Per the FY2024 Medical Devices segment MD&A, FreeStyle Libre is Abbott's continuous-glucose-monitoring (CGM) franchise, among the category leaders per the segment-revenue disclosures. Libre 3 and Libre 3 Plus expansion into over-the-counter channels in select markets per 2024 company press releases extends the addressable user base.
Per the FY2024 Medical Devices segment disclosures, Abbott operates interventional cardiology (MitraClip transcatheter mitral repair, TriClip tricuspid repair, Navitor TAVR), cardiac rhythm management (Aveir leadless pacemaker, ICDs), and related vascular/neuromodulation products. Multi-product cardiovascular presence is the franchise depth.
Per the FY2024 Diagnostics segment MD&A, Abbott's install base of Alinity core-laboratory, rapid (BinaxNOW, ID NOW), and point-of-care instruments drives reagent-and-consumables revenue across clinical and retail-pharmacy settings. The razor-blade-style aftermarket annuity is a structural margin support.
Goodwill of $23.1B on $81B assets equals 28.4% per the FY2024 balance sheet — elevated, reflecting principally the 2017 St. Jude Medical acquisition ($25B per the closing press release) and the Alere acquisition (2017 per the closing announcement).
Moat strength scores 85/100. Abbott's moat is diversification with technical depth, not one overwhelming blockbuster. Libre gives it a fast-growing diabetes platform, structural heart and rhythm-management products embed the company in specialist workflows, diagnostics adds an instrument-and-consumables loop, and nutrition plus established pharma broaden the cash base. That mix makes Abbott harder to disrupt than a single-therapy or single-device story.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $6.4B (OCF $8.6B minus capex $2.2B) supports the dividend and the share-repurchase program disclosed in the capital-return section.
$2.2B capex on $42.0B revenue equals 5.3% — reflecting ongoing manufacturing investment across the Libre CGM lines, diagnostics instrument production, and nutrition facilities disclosed in the property-and-equipment footnote.
Per the FY2024 dividend-history disclosure and S&P Dividend Aristocrat index membership, Abbott has increased its dividend for more than 50 consecutive years — qualifying for Dividend King designation per the conventional screening rules published in financial-media indexes.
Per the FY2024 balance sheet, ROE of 28.1% is robust and supported by the diverse-franchise operating profile plus historical M&A-integration value capture disclosed in successive 10-K segment footnotes.
Capital allocation scores 82/100. Abbott's capital allocation is unusually steady for a healthcare company with this many moving parts: it funds manufacturing, product expansion, bolt-on integration and the dividend without any single bet dominating the file. The question is not whether management can keep returning capital; it is whether future dollars are best spent behind Libre and devices or on another meaningful acquisition.
Key Risks
Per the FY2024 Diagnostics segment MD&A, the post-pandemic normalization in COVID-testing revenue has reduced the segment revenue contribution versus the FY2021-22 peak. The core-lab and rapid-test non-COVID demand trends provide the underlying baseline.
Per publicly-docketed preterm-infant-formula necrotizing enterocolitis (NEC) litigation involving Abbott's Similac products alongside Mead Johnson/Reckitt's Enfamil, the pending mass-tort exposure has been tracked in trade-press and public court dockets. Trial outcomes and insurance coverage are the principal variables.
Per the FY2024 Medical Devices segment Risk Factors and industry commentary, Abbott's FreeStyle Libre competes with Dexcom G-series CGM products. The category has grown with Type 2 diabetes coverage expansion; competitive dynamics on sensor accuracy, pricing, and pharmacy-channel positioning are tracked quarterly in industry trade press.
Per the FY2024 balance sheet, $23.1B goodwill concentrates impairment risk on the St. Jude Medical and Alere reporting units per the acquisition-related purchase-price allocations. Impairment testing follows the disclosed policy.
Risk profile scores 72/100 (higher = safer). Per the FY2024 10-K, the principal watch-items are (1) post-COVID Diagnostics segment normalization disclosed in MD&A, (2) pending preterm-infant-formula NEC mass-tort litigation per publicly-docketed court filings, (3) CGM category competition with Dexcom tracked in industry trade press, and (4) the 28.4% goodwill concentration from St. Jude Medical and Alere acquisitions.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.